Key Takeaways One shot a month of an experimental drug yielded promising results in a new clinical trialThe drug, called ...

The global GLP-1 agonists market, valued at USD 19.70 billion in 2024, is projected to grow at a CAGR of 10.20% to reach USD 52.03 billion by 2034. Driven by rising type 2 diabetes and obesity rates, ...

To get a sense of who is truly in control of Amgen Inc. (NASDAQ:AMGN), it is important to understand the ownership structure of the business. The group holding the most number of shares in the company ...

Cantor Fitzgerald reaffirmed a neutral rating on Amgen, setting a $305 price target for the medical research firm. Despite ...

Retired pro football hall-of-famer Barry Sanders revealed he had a heart attack in 2024. But now he working to help other ...

The apartments are much needed in the neighborhood, where the life sciences sector has grown, but housing hasn't always kept ...

Dr. Jeffrey Kopin, Chief Medical Officer for Northwestern Medicine Lake Forest Hospital, joins John Williams to talk about ...

Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether ...

In a statement on Monday, Amgen Inc. (NASDAQ:AMGN) announced that its phase 2 study of its weight loss drug candidate, ...

Full Phase 2 study results showed side effects that led people to stop treatment with MariTide, as well as weight loss ...

While Amgen’s monthly obesity candidate MariTide helped patients lose significant amounts of weight in a phase 2 study, ...

Amgen plans to proceed with Phase 3 trials, initiating patients on a lower dosage that will gradually increase over an ...